The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"Although there is currently no clinical data on the frequency and mechanism of post-COVID-19 pulmonary fibrosis, it is estimated to be affecting around one-third of the patients hospitalized with SARS-COV-2" source: this article https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785952/
NXP002 is a novel inhaled treatment for pulmonary fibrosis
Patience. And if you don't understand (some very basic concepts of) science please do not post - some of the comments on here today are at a Trump level of understanding. This is a good company with a range of good diagnostic products - both Covid and otherwise. DYOR
best comment on here was 'this is investing. not betting'. If you have done your research and invested here then just chill out and wait. I am invested and relaxed. Lots to come by end of 2020 and more in 2021.